

> Gene expression profiling: A new approach to identifying high-risk patients with melanoma and squamous cell carcinoma



**Friday,
May 17th, 2024**



7:30pm Dinner Presentation



Dallas Room

located in the Hilton McLean Tysons Corner
7920 Jones Branch Drive
McLean, Virginia 22102



Eric Whitman, MD, FACS

System Medical Director,
Atlantic Health System
Cancer Care Director,
Atlantic Melanoma Center

RSVP to MJ Zwarycz

(703) 989-4085 | mzwarycz@castlebiosciences.com

Eric Whitman, MD, FACS

Eric Whitman, MD is a melanoma and advanced skin cancer specialist, based in Morristown, New Jersey. He is currently the Director of the Atlantic Melanoma Center, and the System Medical Director of the entire oncology program for Atlantic Health System. He is active clinically and in research and treats over 400 patients a year with newly diagnosed melanoma and skin cancer.

DecisionDx-Melanoma:

The DecisionDx-Melanoma tests predicts risk of recurrence or metastasis that can inform decisions on the risk of sentinel lymph node positivity and the intensity of follow-ups, surveillance imaging, referral and adjuvant therapy for patients with invasive cutaneous melanoma. The test uses tumor biology to provide an individual risk of melanoma recurrence beyond traditional factors such as AJCC staging criteria and sentinel lymph node status and is supported by consistent evidence in over 25 peer-reviewed publications including two metaanalyses showing Level 1A evidence classifications.

DecisionDx-SCC:

The DecisionDx-SCC predicts metastatic risk for patients with cutaneous squamous cell carcinoma who have one or more risk factors. The test complements factors commonly used for risk assessment in SCC. The incorporation of DecisionDx-SCC results with traditional risk factors provides additional risk prediction to better inform choices about treatment and follow-up care.